HOME
CAREERS
CONTACT US
KOREAN
ENGLISH
KR
EN
Toggle navigation
COMPANY
ABOUT US
KEY MEMBERS
HISTORY
BOARD OF DIRECTORS
SCIENTIFIC ADVISORY BOARD
SCIENCE
NT-I7
NeoBase
NT2020
NT3020
NT4010
NT5010
PIPELINE
Clinical
R&D
COLLABORATION
INVESTORS
NOTICE
PRESENTATION
GENERAL MEETING
OF STOCKHOLDERS
INDEPENDENT
AUDITOR'S REPORT
CONTACT IR
MEDIA
NEWS
VIDEO SOURCE
ESG
OVERVIEW
ENVIRONMENTAL
SOCIAL
GOVERNANCE
NEWS
HOME
MEDIA
NEWS
NEWS
Total
101
71
NeoImmuneTech to Present New Advances on NT-I7 (efineptakin alfa) at 2022 SITC Annual Meeting
2022-10-06
70
QUARTERLY UPDATE (Q3 2022)
2022-10-04
69
NeoImmuneTech’s NT-I7 Creates a More Immunogenic Tumor Microenvironment when Associated with Pembrolizumab
2022-09-13
68
NeoImmuneTech Welcomes New Members to its Scientific Advisory Board
2022-08-08
67
NeoImmuneTech to Present at Cytokine-Based Drug Development Summit
2022-07-26
66
FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech’s NT-I7 for the treatment of Glioblastoma Multiforme
2022-07-13
65
QUARTERLY UPDATE (2Q 2022)
2022-07-12
64
Interest of Combining NeoImmuneTech’s Lead Asset NT-I7 (efineptakin alfa) with Pembrolizumab keeps Growing
2022-07-04
63
NeoImmuneTech to Display its Environmental, Social, and Governance Activities on its Corporate Website
2022-06-30
62
A Study in Nature Communications Reports that NeoImmuneTech's NT-I7 Enhances CAR-T Cell Expansion, Persistence and Anti-tumor Activity
2022-06-15
1
2
3
4
5
>
>>
Search